ClinicalTrials.gov
Cure8 trial brief
Why This Matters
The trial tests a palatable elemental diet (mBIOTA) as a non-drug approach for treating outpatient IBD flares, which could reduce reliance on steroids and other medications if shown effective and tolerable.
Who Should Pay Attention
Adults with Crohn's disease or ulcerative colitis experiencing outpatient flares, gastroenterology clinicians and dietitians, and researchers interested in nutritional therapies for IBD.
Study Snapshot
Story typeClinical Reference
Trial phaseNA
Enrollment42 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
The EDICT trial will randomize adults with Crohn's disease or ulcerative colitis experiencing outpatient flares to either a two-week supply of the mBIOTA elemental diet or usual diet with dietitian counseling. The study plans to enroll 42 participants and measures changes in symptom scores (SCCAI for UC and HBI for CD) over 12 weeks.
The record emphasizes that prior elemental-diet studies in adults have been limited by poor palatability and adherence; mBIOTA is presented as a more palatable formulation with higher adherence in prior small studies. This trial is not yet recruiting and does not report results. Practical note: This is a trial record (not a published result).
It describes eligibility, planned intervention, and outcome measures but does not provide efficacy or safety findings.
Keep In Mind
This is a ClinicalTrials.gov trial record for a study that is not yet recruiting and does not report results. Elemental diets have shown benefit in some pediatric CD studies but adult data are limited; palatability and adherence have been major barriers. The trial’s small planned enrollment (42) means results would be preliminary.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorWake Forest University Health Sciences
Trial IDNCT07143188
Study typeInterventional
Trial phaseNA
Enrollment42 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedJul 29, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A very common vitamin has surprised scientists and is forcing them to rethink how to manage inflammation in Crohn’s disease and colitis
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
What to Know Before Enrolling in a Clinical Trial
Clinical trials are how new IBD tests and treatments are developed; joining one can give access to interventions and helps improve care for people with Crohn’s disease or ulcerative colitis. The article gives practical...